GSK plots Blenrep’s return with more data on its ADC for multiple myeloma
CHICAGO — GSK said its multiple myeloma drug Blenrep combined with other treatments helped reduce the risk of disease progression or death by almost 50% compared …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
